WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has again passed the GMP inspection by Japan's ...

India's contract drug makers have urged the government to remove regulatory hurdles and grant faster clearance to vital raw ...

KØBENHAVN, DENMARK / ACCESS Newswire / February 27, 2025 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark, 27 February 2025 - FluoGuide A/S ("FluoGuide" or the "Company") hereby publishes its annual ...

India's contract drug makers have urged the government to remove regulatory hurdles and grant faster clearance to vital raw ...

India's CRDMO sector is projected to reach US$ 25 billion by 2035, driven by cost advantages, fast project startups, and growing biologics expertise, strengthening its global pharma innovation role.

The debate on MSCs, mesenchymal stromal cells versus mesenchymal stem cells, continued for more than two decades (since 2006), being the major obstacle for MSCs study and clinical application. The ...

Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical ...

India currently holds a 2-3 per cent share of the USD 140-145 billion global CRDMO market but has the potential to become a ...

Union Minister Sarbananda Sonowal announced Rs 4,800 crore for developing waterways in Assam over the next 5 years, including ...

India’s Contract Research Development and Manufacturing Organisation (CRDMO) sector is at an inflection point, with ...

India's CRDMO sector is poised for significant growth, with potential to reach USD 25 billion by 2035, driven by de-risking ...